DUBLIN--(BUSINESS WIRE)--The "Viral Vector Manufacturing Market - Growth, Trends, COVID-19 Impact, and Forecasts (2021 - 2026)" report has been added to ResearchAndMarkets.com's offering.
The Viral Vector Manufacturing Market was estimated to be USD 601.36 million in 2020 and is poised to grow at a CAGR of 27.36% by 2026 to reach USD 2,579.85 million.
The COVID-19 pandemic has underlined the importance of vaccine development for the global population. According to the World Health Organisation (WHO), around 151 vaccine candidates have been subjected to preclinical studies and 42 vaccines have reached clinical trials. The importance of viral vector manufacturing is highlighted by the fact that there are at least two adenovirus-based vaccine candidates that are currently in phase III development while another one has been approved in Russia.
Due to the relative ease of manufacturing viral vector vaccines, effective packaging cell line systems have been developed for many viral vector systems such as Ad (adenoviruses), AAV (Adeno-associated viruses), flaviviruses, and lentiviruses. This has also facilitated the rapid and efficient large-scale production of vaccine candidates that are eligible for clinical applications against COVID-19. In July 2020, an article was published in the 'Nature' journal where the chimpanzee Ad vector ChAdOx1 nCoV-19 was engineered to express the SARS-CoV-2 S protein. When this protein was subjected to immunization of mice and rhesus macaques, it induced strong humoral and cellular immune responses and prevented COVID-19 pneumonia in macaques. More such research involving viral vectors is expected to continue at least for the next one or two years. This is expected to boost market growth.
The factors that are driving market growth include the rising prevalence of genetic disorders, cancer, and infectious diseases, the increasing number of clinical studies using viral vectors, and the availability of funding for gene therapy development, and potential applications in novel drug delivery approaches.
There is also an increase in several genetic disorders and infectious diseases. For instance, according to the UNAIDS Statistics, in 2019, 38.0 million people worldwide were living with HIV and 1.7 million people became newly infected with HIV. According to the same source, 26 million people were accessing antiretroviral therapy at the end of June 2020. In addition, recombinant viral vectors are highly efficient carriers of sequences encoding virus-disabling sequences. Appropriate viral vectors usually need to be selected and adapted for application for the treatment of specific viral infections. Moreover, retroviral gene therapy is a promising alternative treatment for HIV/AIDS. Foamy virus (FV) vectors are derived from non-pathogenic viruses, and they have been used to deliver HIV-inhibiting transgenes to human HSCs. There have been significant public and private sector initiatives for the development of viral vector vaccines. In fact, many companies are investing in capacity expansion for manufacturing activities. For example, in November 2020, the contract manufacturer Vibalogics announced plans to invest USD 150 million to build a 110,000 square-foot facility near Boston in the United States. The facility will be used to produce clinical and commercial-stage oncolytic viruses and viral vectors. Developments such as these are expected to boost the market growth.
Government initiatives are also driving the market's growth. These include efforts through direct funding which is increasing awareness while the regulatory environment is getting streamlined via changes, such as fast track approval processes. Hence, the market for viral vector manufacturing is expected to grow in the future.
Key Topics Covered:
1 INTRODUCTION
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Rising Prevalence of Genetic Disorders, Cancer, and Infectious Diseases
4.2.2 Increasing Number of Clinical Studies And Availability of Funding For Gene Therapy Development
4.2.3 Potential Applications in Novel Drug Delivery Approaches
4.3 Market Restraints
4.3.1 High Cost of Gene Therapies
4.3.2 Challenges in Viral Vector-manufacturing Capacity
4.4 Porter's Five Forces Analysis
5 MARKET SEGMENTATION
5.1 By Type
5.2 By Disease
5.3 By Application
5.4 Geography
6 COMPETITIVE LANDSCAPE
- Cognate BioServices Inc. (Cobra Biologics)
- Finvector
- Fujifilm Holdings Corporation (Fujifilm Diosynth Biotechnologies)
- Kaneka Corporation (Eurogentec)
- Merck KGaA
- Uniqure NV
- Oxford BioMedica Plc.
- Sanofi SA
- F. Hoffmann-La Roche Ltd (Spark Therapeutics)
- Thermo Fisher Scientific Inc.
7 MARKET OPPORTUNITIES AND FUTURE TRENDS
For more information about this report visit https://www.researchandmarkets.com/r/umnhqi
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
